Hot Industry Updates: Kunyao Integrates China Resources Shenghuo; Junshi Biosciences Expands PD-1 Indications; 'First AI Pharma Stock' Lists in Hong Kong

Jun 15, 2024 11:34 CST Updated 11:34

XtalPi

Computation-Driven Innovative Drug R&D Provider

Junshi Biosciences

Innovative Drug Developer

Review of Hot Content

Click on each section title to view the original text details.

1.791 Billion! From Xuesaitong to Notoginseng Industry, Behind the Restructuring of KPC Pharmaceuticals and CR Sanjiu

CR Sanjiu to Sell 51% Stake in Kunming CR Shenghuo Pharmaceutical Co., Ltd. to KPC Pharmaceuticals, Inc. for RMB 1.791 BillionKpc Pharmaceuticals, Inc.This will further integrate the traditional Chinese medicine resources under China Resources Sanjiu, thereby achieving strategic and professional integration of the notoginseng business.

KPC Pharmaceuticals, Inc. stated that this transaction will fully utilize the synergistic advantages between the company and CR Sanjiu in products, channels, brands, and supply chains, continuously expanding the company's business scale in the field of cardiovascular and cerebrovascular disease treatment and steadily enhancing its performance in the "elderly health-chronic disease management" sector. It will also address the issue of competition in the Xuesaitong Soft Capsules product between KPC Pharmaceuticals and CR Sanjiu.

"First AI Drug Development Stock" Listed in Hong Kong Today, Market Value Exceeds 20 Billion

XtalPi, known as China's First AI-Driven Drug Discovery Company to Go Public and the First Technology Firm to List on the Hong Kong Stock Exchange under Rule 18C, officially began trading on the Hong Kong Stock Exchange on June 13.

XtalPi is an innovative R&D platform based on quantum physics, empowered by artificial intelligence and driven by robotics. It provides drug and material science R&D solutions and services to global and Chinese companies in industries such as pharmaceuticals and material science (including agrotechnology, energy, new chemicals, and cosmetics) through intelligent and automated approaches.

Junshi Biosciences' PD-1 Adds New Indication!

On June 12, the website of the National Medical Products Administration (NMPA) showed that the new indication application for Toripalimab, developed by Junshi Biosciences in combination with etoposide and platinum-based chemotherapy (ES-SCLC), for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), has been approved. This is already the ninth approved indication for Toripalimab.

At the same time, the primary endpoints of progression-free survival and overall survival in the multi-center, randomized, open-label, positive drug-controlled Phase III clinical trial of Junshi Biosciences' toripalimab combined with bevacizumab for first-line treatment of advanced hepatocellular carcinoma have reached the pre-specified superiority boundary. The company plans to submit a new drug application for this new indication to regulatory authorities in the near future. This indicates that the marketing of toripalimab’s 10th indication has also been put on the agenda.

Medtide Submits Listing Application to HKEX, Ranked as the World’s Third-Largest CRDMO, with Net Profit Declining Year by Year

Recently, Medtide Inc. (Taide Pharmaceuticals (Zhejiang) Co., Ltd.) submitted a prospectus to the Hong Kong Stock Exchange, planning to list on the Main Board of Hong Kong. Morgan Stanley and CITIC Securities are the joint sponsors of the company.

The prospectus shows that, in terms of sales revenue in 2023, Medtide is the world's third-largest contract research, development, and manufacturing organization (CRDMO) focused on peptides, providing full-cycle services from early discovery, preclinical research, and clinical development to commercial production.

From 2021 to 2023, Medtide's operating revenue was approximately RMB 282 million, RMB 351 million, and RMB 337 million, respectively; the corresponding net profits for the same periods were approximately RMB 80.278 million, RMB 53.98 million, and RMB 48.905 million, respectively.

Medtide's IPO Terminated

On June 12, the official website of the Shenzhen Stock Exchange showed,Dijia Pharmaceutical Group Co., Ltd.And the sponsor, Minsheng Securities, withdrewGrowth Enterprise MarketApplication for listing terminated.

Dijia Pharmaceuticals is a pharmaceutical company dedicated to the research, production, and sales of active pharmaceutical ingredients and intermediates.

The company's main API products include loxoprofen sodium, telmisartan, febuxostat, levamlodipine besylate, fudosteine, glipizide, candesartan cilexetil, flunarizine hydrochloride, atomoxetine hydrochloride, etc., covering the fields of musculoskeletal system, cardiovascular system, gastrointestinal and metabolism, respiratory system, and nervous system based on the downstream preparation’s site of action and mechanism.

At the same time, the company also operates in the business of pharmaceutical intermediates such as dimidazole, para-bromomethyl isophthalic acid, and a small amount of biologics business.

$1.71 Billion! AbbVie Acquires Preclinical TL1A Antibody from Mabwell Biotherapeutics

On June 13, AbbVie announced that it had signed a licensing agreement with MabGenesis to co-develop FG-M701, a next-generation TL1A antibody in preclinical development for the treatment of inflammatory bowel disease (IBD).

Under the terms of the agreement, AbbVie will obtain the exclusive global license for the development, manufacturing, and commercialization of FG-M701. Mabwell Bio will receive $150 million as an upfront payment and near-term milestone payments, and is eligible to receive up to an additional $1.56 billion in clinical development, regulatory registration, and commercialization milestone payments, as well as tiered royalties of up to a low double-digit percentage of net sales.

IBD is a non-specific chronic intestinal inflammation of unknown etiology, with common symptoms including severe abdominal pain, diarrhea, malnutrition, etc. Not only that, IBD can also affect other parts of the body, such as joints, eyes, mouth, liver, gallbladder, and skin, while potentially increasing the risk of cancer in the affected areas of the intestine.

END

◆ NewKangjie widely solicits contributions, which can cover topics related to the pharmaceutical industry such as pharmaceutical policies, R&D trends, and the capital market. Please send your submissions to (hejing@sinohealth.cn) and include your contact information.

◆ Business Cooperation/Reprint OpeningWhite, please contact 13610303540 (same number on WeChat).

Click below to followXinkejie, Get MoreHotspot AnalysisAnalysis/Industry ResearchReport/Blue Book。

[Disclaimer]

1. Some articles on "Xinkejie" are reproduced from the Internet for the purpose of conveying more information, and do not imply agreement with or verification of the authenticity of their content. If you have any questions about the content, please contact our company in a timely manner.
2. "Xinkejie" is committed to providing reasonable, accurate, and complete information, but does not guarantee the reasonableness, accuracy, or completeness of the information, and assumes no responsibility for any loss or damage caused by unreasonable, inaccurate, or omitted information.
3. All information on "Xinkejie" is for reference only and should not be used as the basis for any commercial transactions or medical services. If there are any discrepancies resulting from the independent use of "Xinkejie" content, our company assumes no responsibility, including but not limited to legal and compensation liabilities.
4. For issues not covered in this statement, please refer to relevant national laws and regulations. In case of any conflict between this statement and national laws and regulations, the latter shall prevail.